Navigation Links
Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
Date:4/27/2012

GREENWOOD VILLAGE, Colo., April 27, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion™, Optina™ and Zertane™), licensing distribution of these drugs and developing additional new drugs, today announced that it received notice of allowance of a patent from the US office of patents and trademarks for its DME drug Optina™. Ampio also received a notice of allowance of a similar patent from the Canadian Intellectual Property Office. These initial patents cover the North American territories and multiple additional patents for using Optina™ for the treatment of macular edema and diabetic retinopathy are pending worldwide.

According to Michael Macaluso, Ampio's CEO, "Optina™ is an ultra-low oral (capsule), not commercially available, dose of danazol for the treatment of DME. To our knowledge, no other oral drug to treat this condition exists and there is currently no drug approved by the FDA for this condition. The allowance of these patents in North America is an important step in the development and commercialization of this novel drug as they include multiple claims for the beneficial effects of ultra-low dose Optina™ on vascular hyperpermeability encountered in DME and other vascular leakage syndromes. These patents have an unusually long patent life that expires in 2030. In contrast, most drugs at this stage of development (just before a pivotal trial) have exhausted a large portion of their patent life. These patent claims provide especially strong protection because of the unexpected finding of efficacy only at the very low doses. Ampio is currently in discussions with potential partners to co-develop Optina™ for DME."

Dr. David Bar-Or, Chief Scientific Officer for Ampio, explained, "The mode of action of Optin
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Ampio Strengthens Patent Protection for Lead Drug Ampion™
2. Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule
3. Champions Oncology Reports Fiscal 2012 Third Quarter Financial Results
4. Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011
5. Ampio Pharmaceuticals Schedules 2012 Outlook Webcast
6. Executive Changes at Ampio
7. Ampio Pharmaceuticals Schedules Webcast to Update Shareholders
8. Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million
9. Ampio Responds to Recent Publications by Anonymous Short Sellers
10. Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
11. FDA Advisory Panel Recommends Against Approval of Champion® Heart Failure Management System for Patients With Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 Isis Pharmaceuticals, Inc. ... today announced that management will present a company overview at ... Conference on Thursday, May 30, 2013 at 8:40 a.m. ET ... live audio webcast of the presentation will be available on ... www.isispharm.com .  A replay will be available on the ...
(Date:5/23/2013)... TUCSON, Ariz. , May 23, 2013 ... world,s first and only FDA, Health Canada and CE ... announced today that the Glasgow Science Centre in ... visitors annually, is featuring the SynCardia temporary Total ... as part of its $3 million Bodyworks Exhibition, one ...
(Date:5/23/2013)... , May 23, 2013   BioLife Solutions , ... proprietary clinical grade hypothermic storage and ... contract aseptic media manufacturer , today announced its ... Regenerative Medicine Congress 2013 this week in ... ) Dr. Aby J. Mathew, BioLife,s Senior ...
Breaking Medicine Technology:Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference 2Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 2Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 3BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 2BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 3
... CutisPharma, Inc. announced the introduction of FIRST® - ... 6oz compounding kits. These products expand the FIRST® Magic ... includes FIRST® - Mouthwash BLM 8oz, Duke,s Mouthwash, ... in FIRST® - Mouthwash BLM are comparable to ...
... CITY, Nev., Dec. 21, 2011   Denali Concrete Management ... commenced patient enrollment for a phase 3 clinical study ... orally, in patients with moderate-to-severe Dry Eye Syndrome. This ... Europe and Israel. The randomized, double-masked clinical trial will ...
Cached Medicine Technology:CutisPharma Launches New Prescription Mouthwash Kits Expanding Product Line 2Denali Concrete Management Inc. Announces the Commencement of Patient Enrollment for the Phase 3 Dry Eye Syndrome Study 2
(Date:5/23/2013)... TX (PRWEB) May 23, 2013 Hormones drive ... mood, muscle tone, fat build-up, sleep quality, sex drive, how ... we are getting older are driven by declining hormone levels ... for dehydroepiandrosterone, is the most abundant foundation or base from ... the body gradually increase until about age 25, when we ...
(Date:5/23/2013)... May 23, 2013 During pregnancy both ... are affected by medical treatments, especially medication. In ... Journal of Medicine prompted the FDA to warn about ... birth defects such as persistent pulmonary hypertension and other ... serotonin reuptake inhibitor (SSRI) drugs. SSRI antidepressants are ...
(Date:5/23/2013)... DC (PRWEB) May 23, 2013 A ... drug benefits in Florida’s Medicaid program could save $2.1 ... patients receive. The new report shows that Florida and ... the tools Medicare, unions, and employers rely on to ... the study and Medicaid pharmacy at MedicaidPharmacySavings.com . ...
(Date:5/23/2013)... AZ (PRWEB) May 23, 2013 Looking for ... dealing with the sensitive issue of caring for your aging ... Geriatric Care Managers (NAPGCM) released the results of a ... this question. , Here are the top ... (along with the percentage of survey respondents selecting each option): ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 As Stryker ... Rejuvenate and ABG II Modular-Neck Hip Stems continue to mount ... new research has found a connection between the type of ... The study, which was published on May 15th in ... hips in 11 patients who reported new-onset and increasing ...
Breaking Medicine News(10 mins):Health News:Health2Go Announces Research That DHEA Helps Depression 2Health News:Health2Go Announces Research That DHEA Helps Depression 3Health News:Health2Go Announces Research That DHEA Helps Depression 4Health News:Personal Injury Law Firm Releases Graphic with the Latest Information on Antidepressants and a Possible Risk of Birth Defects 2Health News:Personal Injury Law Firm Releases Graphic with the Latest Information on Antidepressants and a Possible Risk of Birth Defects 3Health News:PCMA: Upgrading Medicaid Drug Benefits Could Save Florida $2.1 Billion 2Health News:New Survey of Aging Experts Gives Top 5 Tips for Avoiding Family Feud when Caring for Aging Parents 2Health News:Stryker Hip Lawsuit News: Bernstein Liebhard LLP Comments on Research Linking Femoral Stem Corrosion at Modular-Neck Junction with Local Soft Tissue Destruction 2Health News:Stryker Hip Lawsuit News: Bernstein Liebhard LLP Comments on Research Linking Femoral Stem Corrosion at Modular-Neck Junction with Local Soft Tissue Destruction 3
... should be made aware, researcher says , , WEDNESDAY, ... twins, those conceived through assisted reproductive technology (ART) are ... intensive care, finds a new study. , Researchers analyzed ... Western Australia between 1994 and 2000. , "We found ...
... (OTC Bulletin Board: MLSS), the recognized leader in advanced injection ... is scheduled to be held on Thursday, June 4, 2009 ... as of the close of business on April 10, 2009. ... of Brown, Rudnick, Berlack and Israels located at 7 Times ...
... LAS VEGAS, May 21 CPC of America, Inc. ... its first patent of a synthetic sealant for specific ... on the development and testing of the MedClose(TM) VCS, ... percutaneous intravascular diagnostic and interventional procedures. In addition, ...
... (Pink Sheets: SCLL) ACTIVTox(R) human liver toxicity tests are ... human liver cell line to identify potential toxicities associated ... available now and can be used to help prevent ... our ACTIVTox testing system could help prevent recalls associated ...
... Jewelry As Their Lucky CharmLOS ANGELES, May 21 It ... the twinkle in their toes that synched the win for ... 8 finale of "Dancing With the Stars." Both Shawn Johnson ... -- designed to boost luck and clarity -- during the ...
... Clients Optimize Resources With Imaging, Behavioral and Chronic ... healthcare is now easier for providers and payors, ... the new Milliman Care Guidelines (R) 13th ... quality measures within the Care Guidelines, ...
Cached Medicine News:Health News:Fertility Treatment Twins More at Risk for Hospitalizations 2Health News:Milestone Scientific to Host 2009 Annual Meeting of Stockholders on Thursday, June 4, 2009 in New York City 2Health News:CPC Files Patent for Synthetic Sealant for the MedClose(TM) Vascular Closure System (VCS) 2Health News:CPC Files Patent for Synthetic Sealant for the MedClose(TM) Vascular Closure System (VCS) 3Health News:FDA's Hydroxycut Recall Highlights the Need for Stem Cell Innovations' ACTIVTox Human Liver Testing 2Health News:FDA's Hydroxycut Recall Highlights the Need for Stem Cell Innovations' ACTIVTox Human Liver Testing 3Health News:Champions Shawn Johnson & Phil Jackson Wear Energy Muse Jewelry 2Health News:Milliman Care Guidelines(R) Products Drive Efficiency Through Expanded Quality Tools 2Health News:Milliman Care Guidelines(R) Products Drive Efficiency Through Expanded Quality Tools 3
... is a uniquely designed two-piece inflatable prosthesis ... in the corpora cavernosa and a single ... simply squeeze the pump to inflate and ... This closed, fluid-filled system allows for good ...
Only Mentors reusable Alpine Leg Bag has patented Kraylex odor barrier, offset port options, and integrated loops providing total confidence and comfort....
Only Mentors reusable Alpine Leg Bag has patented Kraylex odor barrier, offset port options, and integrated loops providing total confidence and comfort....
... Freedom leg bags are part ... a versatile line of leg bags, ... the varied needs of our customers. ... several sizes, and constructed of 100% ...
Medicine Products: